Step 1 topics → Psychiatry → Atypical Antidepressants (Bupropion, Mirtazapine, Trazodone)

Atypical Antidepressants (Bupropion, Mirtazapine, Trazodone)

USMLE Step 1 trap: Confuses bupropion's dopamine/norepinephrine mechanism with serotonergic antidepressant mechanisms. Bupropion inhibits reuptake of dopamine and norepinephrine (NRI/DRI), with no significant serotonergic activity, which explains its lack of sexual side effects and its utility in smoking cessation.

Atypical antidepressants are a mechanistically diverse group that the USMLE Step 1 loves to test precisely because they don't fit the SSRI/SNRI mold. Bupropion, mirtazapine, trazodone, and vortioxetine each have distinct receptor profiles, distinct side effect signatures, and distinct clinical niches — and the exam exploits all three. You need to know not just what they do, but WHY they're chosen over alternatives (e.g., why bupropion for a patient who can't tolerate sexual side effects, why mirtazapine for the depressed patient who's also underweight and can't sleep).

The trickiest part is that students lump these drugs together as 'antidepressants that aren't SSRIs' and stop there. That's exactly where the exam catches people. Bupropion's mechanism is dopaminergic/noradrenergic — zero serotonin — which is why it doesn't cause sexual dysfunction and why it works for smoking cessation. Mirtazapine doesn't inhibit reuptake at all; it increases neurotransmitter release by blocking presynaptic alpha-2 receptors. Trazodone's clinical use has shifted almost entirely to insomnia at sub-antidepressant doses, and its serious adverse effect (priapism) comes from alpha-1 blockade, not its serotonergic activity.

On USMLE Step 1, these drugs appear in two main formats: direct mechanism/side-effect recall (which drug causes what), and clinical vignettes where you pick the right agent given a patient's comorbidities or contraindications. The contraindication angle is especially high-yield — bupropion in a patient with bulimia or a seizure history is a classic trap. Know each drug's mechanism cold, then layer on the clinical pearls.

From real student decks
59%have cards covering this topic
46%have mature cards
2.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: Bupropion works by inhibiting serotonin reuptake like SSRIs.
Right: Bupropion inhibits reuptake of dopamine and norepinephrine (NRI/DRI), with no significant serotonergic activity, which explains its lack of sexual side effects and its utility in smoking cessation.
Bupropion has no clinically relevant serotonergic activity — grouping it mentally with SSRIs will get you burned on the exam. It works by blocking dopamine and norepinephrine reuptake transporters (NDRI), which is why it lacks the hallmark SSRI side effects (no sexual dysfunction, no weight gain) and why it's effective for nicotine dependence (dopamine reward pathway). When a vignette describes a patient who wants to quit smoking and is also depressed, or a patient who hates their SSRI's sexual side effects, bupropion is the answer because of this distinct mechanism.
Common mistake
Gap: Missing knowledge of bupropion's seizure-lowering contraindications, especially in eating disorders
Bupropion lowers the seizure threshold and is contraindicated in patients with eating disorders (electrolyte abnormalities), seizure disorders, and those undergoing abrupt alcohol or benzodiazepine withdrawal.
Bupropion lowers the seizure threshold — this is one of the most tested contraindication facts about any antidepressant. The highest-yield trap is the patient with bulimia nervosa or anorexia nervosa: electrolyte abnormalities (particularly hypokalemia and hypomagnesemia from purging) already predispose to seizures, and adding bupropion is dangerous. The same logic applies to patients with pre-existing seizure disorders or those withdrawing from alcohol or benzodiazepines, both of which independently lower the seizure threshold.
Common mistake
Wrong: Mirtazapine increases norepinephrine and serotonin by blocking their reuptake transporters.
Right: Mirtazapine increases norepinephrine and serotonin release by blocking presynaptic alpha-2 autoreceptors/heteroreceptors, and its H1 blockade causes sedation and weight gain.
Mirtazapine does not touch reuptake transporters — this is the single most common wrong mental model for this drug. Instead, it blocks presynaptic alpha-2 autoreceptors (which normally suppress NE release) and alpha-2 heteroreceptors on serotonin terminals (which normally suppress 5-HT release), so blocking them disinhibits both systems simultaneously. The sedation and weight gain come from potent H1 (histamine) antagonism — which is actually clinically useful in the depressed, underweight, insomniac patient, making mirtazapine a targeted choice rather than just a drug with bad side effects.
Common mistake
Gap: Missing knowledge that trazodone's priapism risk is due to alpha-1 blockade, not serotonergic effects
Trazodone causes priapism via alpha-1 adrenergic blockade in penile vasculature, and is commonly used off-label for insomnia at sub-antidepressant doses.
Priapism from trazodone is not a serotonergic effect — it results from alpha-1 adrenergic receptor blockade in the smooth muscle of penile vasculature, which impairs detumescence. This is the same mechanism as alpha-1 blocker-induced priapism. Trazodone's serotonergic activity (5-HT2 antagonism + weak reuptake inhibition) contributes to its sedating and antidepressant effects, but the priapism adverse effect is a separate, alpha-1-mediated phenomenon. Also lock in that trazodone is overwhelmingly used at low doses for insomnia rather than as a primary antidepressant in current practice.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Bupropion: Know its NDRI mechanism (dopamine + norepinephrine reuptake inhibition, NO serotonin), its indications beyond depression (smoking cessation, ADHD, sexual dysfunction from SSRIs), and its critical contraindications — seizure disorders, eating disorders with electrolyte disturbances, and abrupt alcohol/benzo withdrawal.
  2. Mirtazapine: Understand that it increases NE and 5-HT via presynaptic alpha-2 autoreceptor/heteroreceptor blockade (not reuptake inhibition), and that H1 blockade drives its sedation and weight gain — making it the go-to for depressed patients who are underweight or have insomnia.
  3. Trazodone: Know it is primarily a serotonin antagonist/reuptake inhibitor (SARI), that it's most commonly used off-label for insomnia at low doses, and that priapism is a feared adverse effect caused by alpha-1 adrenergic blockade in penile vasculature — not by its serotonergic actions.
  4. Vortioxetine: Recognize it as a multimodal serotonergic agent (5-HT reuptake inhibitor + direct agonist/antagonist activity at multiple 5-HT receptor subtypes), sometimes marketed for cognitive symptoms of depression — Step 1 tests this as a 'know it exists and what makes it different' concept.

Can you avoid these mistakes?

A 28-year-old woman with major depression and bulimia nervosa presents asking about antidepressant options. She specifically wants to avoid weight gain and sexual side effects. You consider bupropion — what is the critical reason you should NOT prescribe it to her, and what is the mechanism behind that concern?
A physician explains that mirtazapine increases both norepinephrine and serotonin levels. A student says 'oh, so it's like an SNRI.' What's wrong with that explanation, and what is the actual molecular mechanism by which mirtazapine raises synaptic NE and 5-HT?
A 45-year-old man develops a painful erection lasting 4 hours after starting a new psychiatric medication. His chart shows he was started on trazodone for insomnia. What receptor is responsible for this adverse effect, and why does blocking that receptor cause priapism?
Match each drug to its most distinctive clinical niche: (A) Bupropion, (B) Mirtazapine, (C) Trazodone, (D) Vortioxetine — for a patient quitting smoking with comorbid depression; a cachectic depressed patient with severe insomnia; a patient needing low-dose sleep aid who doesn't need antidepressant dosing; a patient where cognitive symptom improvement is the primary marketing claim.

Related topics

Selective Serotonin Reuptake Inhibitors (SSRIs) Major Depressive Disorder (MDD) Persistent Depressive Disorder (Dysthymia) Bipolar I Disorder Bipolar II Disorder

See how your Anki deck covers this topic.

Upload your deck for a free audit →